Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3802731 | 1.00 | AHCY (0.49) | AHCYADORA2AADORA1TRPA1CCNB2 | |
| SCHEMBL2027217 | 0.88 | AHCY (0.47) | AHCYADORA2AADORA1CCNB2CDK1 | |
| SCHEMBL4563686 | 0.77 | ADORA2A (0.41) | AHCYADORA2AADORA1KDM4ELMNA | |
| SCHEMBL7668705 | 0.75 | ADORA2A (0.41) | AHCYADORA2AADORA1KDM4ELMNA | |
| SCHEMBL22399500 | 0.75 | ADORA2A (0.42) | AHCYADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL28763195 | 0.72 | AHCY (0.34) | AHCYADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL6141625 | 0.70 | ADORA2A (0.36) | AHCYADORA2AADORA1KDM4EPI4KA | |
| SCHEMBL15829723 | 0.69 | ADORA2A (0.37) | AHCYADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL4455868 | 0.69 | ADORA2A (0.37) | ADORA2AADORA1KDM4ELMNAPI4KA | |
| SCHEMBL72542 | 0.66 | ADORA2A (0.46) | ADORA2AADORA1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884293-B1 | Fertiliser compositions containing natural or synthetic aminopurine derivatives or seaweed extracts containing these products together with a calcium source | SECMA BIOTECHNOLOGIES MARINES (FR) | 2005-01-05 | — | — | EP | claimed |
| CN-117230113-A | Application of leymus chinensis endogenous regeneration factor combination in genetic transformation and efficient genetic transformation method of leymus chinensis | 中国科学院遗传与发育生物学研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-114145231-B | Rapid propagation method for stropharia bicolor seedlings | 广西壮族自治区中国科学院广西植物研究所 | 2022-09-13 | — | — | CN | disclosed |
| CN-114145231-A | Rapid propagation method for stropharia bicolor seedlings | 广西壮族自治区中国科学院广西植物研究所 | 2022-03-08 | — | — | CN | disclosed |
| EP-1673439-B1 | COMPOSITIONS FOR TREATING FAMILIAL DYSAUTONOMIA BY ALTERING MRNA SPLICING | MASSACHUSETTS GEN HOSPITAL (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9265766-B2 | Methods for altering mRNA splicing and treating familial dysautonomia by administering benzyladenine | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150111902-A1 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia by Administering Kinetin, Benzyladenine, and Tocotrienols | THE GENERAL HOSPITAL CORPORATION (US) | 2015-04-23 | — | — | US | disclosed |
| US-8729025-B2 | Methods for altering MRNA splicing and treating familial dysautonomia by administering kinetin, benzyladenine, and tocotrienols | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120329816-A1 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia and Other Mechanistically Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20110136836-A1 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia and Other Mechanistically Related Disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-1673439-A2 | METHODS FOR ALTERING MRNA SPLICING AND TREATING FAMILIAL DYSAUTONOMIA AND OTHER MECHANISTICALLY RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060014763-A1 | Methods for altering mRNA splicing and treating familial dysautonomia and other mechanistically related disorders | GENERAL HOSPITAL CORPORATION, THE | 2006-01-19 | — | — | US | disclosed |
| WO-2005033290-A2 | METHODS FOR ALTERING MRNA SPLICING AND TREATING FAMILIAL DYSAUTONOMIA AND OTHER MECHANISTICALLY RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-0884293-B1 | Fertiliser compositions containing natural or synthetic aminopurine derivatives or seaweed extracts containing these products together with a calcium source | SECMA BIOTECHNOLOGIES MARINES (FR) | 2005-01-05 | — | — | EP | disclosed |
| EP-0584068-B2 | METHOD AND COMPOSITION FOR AMELIORATING THE ADVERSE EFFECTS OF AGING | SENETEK PLC (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-0584068-B1 | METHOD AND COMPOSITION FOR AMELIORATING THE ADVERSE EFFECTS OF AGING | SENETEK PLC (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0884293-A1 | Fertiliser compositions containing natural or synthetic aminopurine derivatives or seaweed extracts containing these products together with a calcium source | SOCIETE D'ENGRAIS COMPOSES MINERAUX ET AMENDEMENTS (S.E.C.M.A.) (FR) | 1998-12-16 | — | — | EP | disclosed |
| US-5614407-A | ADMINISTERING 6-(SUBSTITUTED AMINO)PURINE CYTOKININS | SENETEK PLC (US) | 1997-03-25 | — | — | US | disclosed |
| US-5602139-A | CONTACTING MAMMALIAN CELLS WITH A COMPOSITION CONTAINING ONE OR MORE 6-(SUBSTITUTED AMINO)PURINE CYTOKININS | SENETEK PLC (US) | 1997-02-11 | — | — | US | disclosed |
| US-5371089-A | Method and composition for ameliorating the adverse effects of aging | SENETEK, PLC (US) | 1994-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136836-A1 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia and Other Mechanistically Related Disorders | RBM17, HNRNPA1, SF1 | AHCY 1470/4885ADORA2A 3391/4885ADORA1 2708/4885 |
| US-20150111902-A1 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia by Administering Kinetin, Benzyladenine, and Tocotrienols | RBM17, SF1, HNRNPA1 | AHCY 428/4885ADORA2A 1484/4885ADORA1 1763/4885 |
| US-20120329816-A1 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia and Other Mechanistically Related Disorders | RBM17, HNRNPA1, SF1 | AHCY 1470/4885ADORA2A 3391/4885ADORA1 2708/4885 |
| US-20060014763-A1 | Methods for altering mRNA splicing and treating familial dysautonomia and other mechanistically related disorders | RBM17, HNRNPA1, SF1 | AHCY 1470/4885ADORA2A 3391/4885ADORA1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.